BHRC BLOG
Provider-Led Peptide & Hormone Protocols — How Medical Supervision Actually Works
BHRC · WELLNESS · PROVIDER-LED PROTOCOLS
There are two versions of peptide and hormone therapy available in 2026, and they look similar from the outside. One begins with blood work, prescribes one thing at a time, names the pharmacy, re-tests you, and sometimes tells you no. The other emails you a protocol and a tracking number. The molecules can be identical; almost nothing else is. This guide sets out what a medically supervised program actually involves — what gets measured and why, why sequential beats simultaneous, what is genuinely available under current US rules, and the questions that will tell you within ten minutes which kind of program you are talking to.
1 · Why supervision is the variable that matters
Peptides, hormones and metabolic medications all share a property that makes them different from an aesthetic treatment: you cannot see whether they are working.
A laser either improved your pigment or it did not, and you can look in a mirror. Testosterone, thyroid support, growth hormone secretagogues and GLP-1 medications all act on systems you have no direct perception of. The only way to know what is happening is to measure it — which is why every meaningful difference between programs comes down to whether anyone is measuring.
2 · What gets measured, and why
The specific panel depends on what you are treating. The principle does not: measure before, measure during, and compare against your own baseline rather than a population range.
3 · One at a time — the rule that produces information
The most common failure in wellness medicine is not a dangerous prescription. It is an uninterpretable one.
Start three agents in the same week and by week six you have a feeling and no data. If you feel better, you cannot say which one did it — so you cannot drop the two that are not helping. If something goes wrong, you cannot say which caused it — so you stop everything and learn nothing. Either way you have paid for an experiment with no result.
4 · What is actually available — and what is not
This is where an honest program separates itself fastest, because the correct answer is often “no.”
Under federal law, a bulk drug substance may be compounded only if it complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List. Several of the most-marketed peptides meet none of those conditions.
5 · Hormones — where supervision is not optional
Hormone replacement is the area where the gap between a supervised program and a prescription mill has the clearest consequences, because the monitoring requirements are well established and the risks of skipping them are specific.
For testosterone therapy, that means tracking hematocrit for erythrocytosis, PSA and prostate assessment as clinically indicated, estradiol, and symptom response — not just a number. For women, menopause care involves its own considerations around route, dose and duration. Both require a conversation about what you are actually trying to change.
The same principle applies across men’s health, menopause care and hormone pellet therapy: the prescription is the easy part. Deciding whether it is the right answer, and then watching what it does, is the practice of medicine.
6 · Where peptides genuinely fit
Nothing here says peptide therapy is a dead end. Some peptides have real mechanisms, real clinical data and clear regulatory standing. Sermorelin, for example, was an FDA-approved product until 2008–2009 and was withdrawn for commercial rather than safety reasons — FDA said so explicitly in a 2013 Federal Register determination.
What the evidence does not support is the marketing version: a menu of twelve peptides, a protocol identical for everyone, and promises about energy, sleep, skin and libido that have never been primary endpoints in any trial.
If you want the detail, we have written it out: the sermorelin guide covers the protocols used in published trials and a realistic results timeline, and the Epitalon guide shows what it looks like when a much-hyped peptide’s evidence is examined closely.
7 · What to ask before you start anything
Physician-supervised peptide, hormone and longevity programs — with baseline and follow-up labs — are available at all six BHRC studios. Consultations are free, include a review of your history and current labs, and carry no obligation.
If what you are asking for is not appropriate or not currently available, we will tell you that.
Programs are anchored at BHRC West Los Angeles, with the same protocols available at West Hollywood, Summerlin and the rest of our locations. All of them begin the same way — with testing.
Frequently Asked Questions
What makes a program ‘provider-led’?
Baseline labs before anything is prescribed, a named prescriber you can reach, one agent at a time at a documented dose, repeat testing on treatment against your own baseline, a licensed compounding pharmacy you can name, and a defined endpoint. If none of those are present, you have a subscription rather than a program.
Why do labs matter so much here?
Because unlike an aesthetic treatment, you cannot see whether these are working. Hormones, secretagogues and metabolic medications act on systems you have no direct perception of. Measurement is the only way to know what is happening, and a single result with no baseline to compare against tells your provider very little.
Why one agent at a time?
Because starting several at once destroys attribution. If you feel better you cannot say which agent did it, so you cannot drop the ones that are not helping. If something goes wrong you cannot say which caused it. Sequential use is slower and it is the only version that produces an answer.
Which peptides can I actually get?
It depends on current regulatory standing, which changes. As of September 2026, BPC-157, TB-500, injectable GHK-Cu and thymosin alpha-1 cannot be lawfully compounded in the US; ipamorelin acetate sits in FDA’s Category 2 for significant safety risks. Ask your provider what is available at the time — and be wary of anyone who offers everything.
Did the July 2026 FDA vote change what is available?
No. An advisory committee voted to recommend six peptides for the 503A Bulks List, against the recommendation of FDA’s own scientists. Advisory votes are non-binding and FDA must complete notice-and-comment rulemaking first. Nothing has legally changed.
Is buying peptides online the same thing?
No. A prescription filled by a licensed compounding pharmacy is materially different from a vial bought from a website. FDA issued warning letters to online peptide sellers in March, June and August 2026, and has described these substances as poorly characterised, with certificates of analysis frequently lacking impurity, aggregation and endotoxin data.
What should be monitored on testosterone therapy?
Total and free testosterone, hematocrit for erythrocytosis, PSA and prostate assessment as clinically indicated, estradiol, and symptom response. Equally important is establishing why a number is low — sleep apnea, obesity, thyroid dysfunction and medication effects can all produce it and are better addressed directly.
What can sermorelin realistically do?
Published trials support raised endogenous GH with preserved pulsatility, dose-dependent IGF-1 increases, and modest body-composition change over months — lean mass up, visceral fat down. They do not support strength or aerobic fitness gains, and sleep, skin and libido have never been primary endpoints in a sermorelin trial.
What should I do before my first appointment?
Bring any recent labs, a full list of medications and supplements, and a clear statement of what you are actually trying to change. Vague goals produce vague protocols.
What if my provider says no?
That is usually a good sign. A practice that has never declined a request is not assessing anyone. The correct answer to some requests is that the substance is not available, not appropriate for you, or not supported by evidence for what you want it to do.
Keep Reading
- Advanced Diagnostic Testing
- Longevity & Healthspan at BHRC
- Sermorelin Dosage Guide: Protocol, Timing & Results Timeline
- Peptide Stacking Guide: Which Peptides Can Be Combined Safely
- FDA Peptide Reclassification 2026 — What It Means for Patients
- Hormone Replacement Therapy at BHRC West Hollywood
- Men’s Health at BHRC
- Menopause Care at BHRC
Provider-Led Programs at a BHRC Studio Near You
Physician-supervised peptide, hormone and longevity programs — with baseline and follow-up labs — are available at BHRC studios nationwide, including our main six. Tap your closest location to book a free consultation:
References & Further Reading
- U.S. Food & Drug Administration — Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (guidance), January 2025. fda.gov
- U.S. Food & Drug Administration — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov
- U.S. Food & Drug Administration — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov
- Federal Register / U.S. Food & Drug Administration — Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 2013. federalregister.gov
- Endotext / NCBI Bookshelf — Fredrick JR et al. Growth Hormone and Aging. ncbi.nlm.nih.gov
- Translational Andrology and Urology — Sinha DK et al. The role of growth hormone secretagogues in the modern management of body composition in hypogonadal males, 2020. tau.amegroups.org
- Frontiers in Aging — Fernández-Garza LE et al. Growth hormone and aging: a clinical review, 2025. frontiersin.org
- DailyMed / U.S. National Library of Medicine — GENOTROPIN (somatropin) prescribing information — contraindications and warnings for growth hormone therapy. dailymed.nlm.nih.gov
- U.S. Food & Drug Administration — Warning Letter — Royal Peptides LLC, August 2026. fda.gov
- U.S. Food & Drug Administration — Warning Letter — Wholesale Peptide, June 2026. fda.gov
- Holland & Knight — FDA Advisory Committee Endorses Compounding of Certain Peptides, August 2026. hklaw.com
Beverly Hills Rejuvenation Center. This content is for general education and does not create a physician-patient relationship or constitute medical advice. Peptide and hormone therapy at BHRC is provided only under physician evaluation and supervision. Several substances discussed are not FDA-approved and are not currently eligible for compounding in the United States; availability changes and is confirmed at consultation. Nothing here is a dosing recommendation. Candidacy, dosing, results and pricing vary by person and are confirmed at a free consultation. Reviewed by the BHRC clinical team.
